Cargando…
Spanlastics as a Potential Platform for Enhancing the Brain Delivery of Flibanserin: In Vitro Response-Surface Optimization and In Vivo Pharmacokinetics Assessment
Flibanserin was licensed by the United States Food and Drug Administration (FDA) as an oral non-hormonal therapy for pre-menopausal women with inhibited sexual desire disorder. However, it suffers from susceptibility to first-pass metabolism in the liver, low aqueous solubility, and degradation in t...
Autores principales: | Alharbi, Waleed S., Hareeri, Rawan H., Bazuhair, Mohammed, Alfaleh, Mohamed A., Alhakamy, Nabil A., Fahmy, Usama A., Alamoudi, Abdullah A., Badr-Eldin, Shaimaa M., Ahmed, Osama A., AlGhamdi, Shareefa A., Naguib, Marianne J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786754/ https://www.ncbi.nlm.nih.gov/pubmed/36559120 http://dx.doi.org/10.3390/pharmaceutics14122627 |
Ejemplares similares
-
Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route
por: Ahmed, Osama A. A., et al.
Publicado: (2020) -
Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin
por: Fahmy, Usama A, et al.
Publicado: (2020) -
Merging Experimental Design and Nanotechnology for the Development of Optimized Simvastatin Spanlastics: A Promising Combined Strategy for Augmenting the Suppression of Various Human Cancer Cells
por: Badr-Eldin, Shaimaa M., et al.
Publicado: (2022) -
Intranasal Niosomal In Situ Gel as a Promising Approach for Enhancing Flibanserin Bioavailability and Brain Delivery: In Vitro Optimization and Ex Vivo/In Vivo Evaluation
por: Fahmy, Usama A., et al.
Publicado: (2020) -
Preparation, characterization, dissolution, and permeation of flibanserin − 2-HP-β-cyclodextrin inclusion complexes
por: Alghaith, Adel F., et al.
Publicado: (2021)